
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Abstract
Phase 2b dose-ranging trial (COMP360) in 233 participants with treatment-resistant depression. The 25 mg psilocybin group showed significantly greater reduction in MADRS depression score at week 3 compared to the 1 mg control group.
Keywords
psilocybintreatment-resistant depressionCOMP360phase 2bCOMPASS Pathways
Clinical Research
